16 September 2026 editorial review · Item
Sinocare iCan i3 / GlucoMen iCan: review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the item evidence page →Thriving evidence review — 16 September 2026
Record: Sinocare iCan i3 / GlucoMen iCan
Scope and findings: Added in the second discovery pass. A15-day standalone CGM sold under regional branding. A2026 pediatric paper reports8.89% MARD in75 per-protocol participants; this does not establish superiority over another CGM or US clearance. Numerical claims are tied to the cited product specifications or named study, and editorial scores do not represent measured comparative performance.
Primary sources checked:
- Sinocare iCan i3 specifications and regional indication
- Wang et al. Pediatric CGM performance study
- Sinocare ADA2026 adult and pediatric reports
- GlucoMen iCan user guide, April2025
- Sinocare product history and i3/i6 launch distinctions
Limits: Scope is the specific claims documented in the new record. Local stock, payer rules, every hardware variant and unreported head-to-head outcomes are not verified. Regulatory status, manufacturer marketing and clinical performance are distinct.